A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Esophagus | Kidney | Melanoma, skin | Pancreas | Stomach | Phase I | Cervix
What is the purpose of this trial?
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
- Trial withKymab
- Start Date09/05/2019
- End Date04/30/2023
- Last Updated08/13/2020
- Study HIC#2000024343